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THE PROGNOSTIC VALUE OF BIOMARKERS IN THE EVALUATION OF 
GLIOBLASTOMA MULTIFORME  
MARC-ANDRE GASCON 
ABSTRACT 
Background 
Glioblastoma multiforme (GBM) is a highly heterogeneous tumor of the central nervous 
system (CNS) that exhibits considerable variation in its clinical course. Recently, the 
World Health Organization (WHO) published a classification system for tumors of the 
CNS that combines histological features with molecular parameters to determine tumor 
grade. The incorporation of molecular biomarkers that carry both prognostic and 
predictive value adds another level of objectivity to the glioma grading system and will 
help guide clinical decision. As such, the assessment of biomarkers has become an 
integral part of tumor evaluation in neuro-oncology. This curriculum will discuss the 
clinical relevance of the most recently studied biomarkers with prognostic and predictive 
value in the evaluation of GBM. Biomarkers regularly used for the assessment of GBM 
include the IDH mutations, MGMT methylation status, and EGFRvIII. Furthermore, this 
review will offer a perspective on experimental approaches currently under investigation 
for treatment of GBM. 
Literature Review Findings 
MGMT methylation of the promoter region is associated with better treatment response 
from temozolomide (TMZ), an alkylating therapeutic. Treatment benefit was most 
prominent in the elderly population and therapy should be individualized for that age 
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group. Patients with GBM characterized by IDH1/IDH2 mutations carry a better overall 
prognosis primarily due to their higher sensitivity to chemo- and radiotherapy. The 
prognostic value of EGFRvIII remains controversial, although it may be associated with a 
worse prognosis. Nonetheless, EGFRvIII provides an ideal target for targeted molecular 
therapies as it is only found on tumor cells. 
Proposed Methods 
A curriculum aimed at educating primary care providers (PCPs) about the most clinically 
significant biomarkers in GBM will be developed. The curriculum will be in a 
PowerPoint format, and the hour-long lecture will be presented at continuing medical 
education national conferences. A pre- and post-test consisting of the same 10 multiple-
choice questions will be administered on a voluntary basis to help evaluate knowledge 
acquisition from the curriculum. Results will be evaluated with a paired t-test analysis. 
The tests will be will be administered through Poll Everywhere, a smartphone survey 
application.  
Conclusion 
There is increasing evidence to suggest that therapies should be individualized according 
to specific biomarkers with predictive value. PCPs are in a position where they are often 
the first providers to suspect the diagnosis of a brain tumor. Therefore, it is imperative for 
PCPs to be aware of the latest development in the field of neuro-oncology so that they 
may appropriately counsel patients. 
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INTRODUCTION 
Background 
Gliomas are malignancy of the CNS that primarily develop within the brain parenchyma. 
They are tumors that share histological features with normal glial cells. GBM, the most 
aggressive and commonly occurring glioma in adults, is generally associated with a poor 
prognosis and rapidly progressing disease1. In the United States, the reported annual 
incidence is 3.2 cases per 100,000 people, and despite its relatively rare incidence, the 
disease is responsible for a disproportionally high level of comorbidities and deaths2. 
GBM has a tendency to affect males and those above 64 years of age2. 
The diagnosis is based on histological features and molecular biomarkers that 
determine the tumor grade and potential for malignancy according to criteria established 
by the WHO3. The WHO classification system for CNS tumors was recently updated 
after recognition that tumors with morphologically similar features may harbor 
significantly different genetic alterations that carry different prognosis. The recent 
addition of biomarkers to the classification has helped redefine tumor subtypes within 
each WHO category and groups together entities with similar biological properties 
regardless of the putative cell of origin3. 
Prognostic biomarkers are used in oncology to predict the likely course of a 
disease without any given intervention. Predictive biomarkers offer information about a 
patient’s likely response to a given therapy. There is increasing evidence that specific 
biomarkers associated with GBM may help guide clinical decisions. 
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Despite recent advancement in genomics, GBM remains an incurable disease and 
invariably results in deterioration of neurological function, ultimately leading to death. 
Following genome-wide analysis studies, several molecular alterations and aberrant 
growth signaling pathways involved in the pathogenesis of GBM have been identified. 
These findings have led to the development of molecular targeted therapies that aim to 
block signal transduction pathways involved in tumor growth, survival, and invasion4. 
However, following the results of multiple clinical trials, it is now becoming evident that 
molecular targeted therapies directed toward a single genetic alteration or signaling 
pathway will unlikely lead to disease remission5.  
Recent successes in proof-of-concept trials have opened the door to new 
therapeutic agents that aim to modulate and enhance the immune response against the 
tumor with the hope that a more durable and long-lasting response can be achieved in 
GBM patients. There is growing interest in the field of immunotherapy, and several 
studies are currently underway to evaluate the use of cell-based vaccines and oncolytic 
viruses that have the ability to target specific biomarkers expressed only on tumor cells.  
In studies thus far, immunotherapies have demonstrated satisfying safety profiles and 
limited adverse effects. However, to date, few large randomized controlled clinical trial 
have been conducted to determine the clinical efficacy of these therapies5. 
Additional research is required before remission can be achieved in GBM. The 
identification and characterization of key biomarkers is an essential step in the 
development of novel therapeutic strategies.  
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Statement of the Problem 
The standard of care for newly diagnosed GBM includes maximal surgical resection to 
the extent possible and radiotherapy plus concomitant and adjuvant TMZ. Despite this 
multimodality treatment, most patients will recur within 6.9 months, and prognosis 
remains poor with a median survival time of only 14.6 months6. Given the poor prognosis 
associated with GBM, it is imperative that basic research continues to identify important 
biomarkers that can lead to clinical trial design and translate into improved clinical 
outcomes for patients.  
The diagnosis of GBM has a drastic impact in a person’s life. Whether a patient 
feels most comfortable discussing his/her diagnosis with a specialist or its PCP with 
whom he or she may have established long-term rapport, it is essential that all health care 
providers are knowledgeable of the most effective therapeutic options that make use of 
the latest developments in the field of neuro-oncology. As such, it is imperative for PCPs 
to understand the value of biomarkers in guiding their clinical decisions and treating their 
patients.  
 
Hypothesis 
Providing a CME curriculum will improve PCPs’ knowledge and help them become 
acquainted with the prognostic and predictive value of specific biomarkers associated 
with GBM. 
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Objectives and specific aims 
Providing a CME curriculum to educate PCPs about the value of well-characterized 
biomarkers associated with better prognosis or treatment responses to GBM will better 
equip clinicians in advising their patients through their disease, providing counsel on 
treatment options, and making appropriate recommendations.   
1. To provide PCPs with a general understanding of the different treatment options 
available and current challenges related to the eradication of GBM. 
2. To improve PCPs’ understanding of biomarkers with prognostic and predictive 
value and ability to educate and counsel patients. 
3. To compare pre and post-test results with a paired t-test analysis in order to 
evaluate knowledge acquisition following the presentation.
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REVIEW OF THE LITERATURE 
Overview 
The brain is composed of both stromal and parenchymal tissue. The stroma plays a 
supportive or structural role. It is composed of both blood vessels that penetrate deeply 
into the brain parenchyma to provide oxygen and nutrients necessary for brain function, 
and connective tissue that provides additional structural support. The brain parenchyma is 
the functional tissue of the brain. It is used for cognition and motor function and is 
composed of neurons and glial cells7. 
Three types of glial cells maintain homeostasis by providing physical and 
metabolic support to the CNS. Oligodendrocytes surround and insulate neurons by 
creating the myelin sheath, while astrocytes provide structural support. Astrocytes are 
also involved in the removal of cellular debris and dead neuron cells, as do microglia, the 
last type of glial cell. Furthermore, astrocytes help maintain optimal neuronal function by 
regulating extracellular fluid composition and supporting the blood-brain barrier, which 
helps protect neural tissue from variations in blood composition and neurotoxic 
substances7. 
Primary brain tumors are neoplasms that originate from the brain tissue itself; 
whereas, secondary brain tumors are neoplasms that originate from somewhere else in the 
body, but involve the brain as a metastatic site. The most common primary brain tumors 
are gliomas, and although certain subtypes are histologically benign, the complexity of 
the brain often blurs the distinction between benign and malignant neoplasm8. A benign 
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tumor with little potential for malignancy may prove to be lethal if located in a region of 
the brain that interferes with vital bodily functions. 
Gliomas are tumors that share histological features with normal glial cells and 
commonly involve the brain parenchyma. Although their origin remains unclear, they 
were traditionally believed to arise from normal glial cells. Recent evidence suggests that 
such tumors may originate from neural stem cells9. 
 
Epidemiology 
 
Various international organizations track the incidence of gliomas through government 
cancer registries or personal health records. However, the complexity of the current 
classification of gliomas with regards to histological features, as well as differences in 
data collection techniques, make comparison among studies a challenge. In the United 
States, the Central Brain Tumor Registry of the United States estimates the annual 
incidence for malignant glioma is approximately 5 cases per 100,000 people. GBM, the 
most common and deadly glioma subtype occurring in adults, accounts for 60 to 70% of 
malignant gliomas with an annual age-adjusted incidence of 3.2 cases per 100,000 
people2,10. Many studies have attempted to determine whether the incidence rate of 
malignant gliomas is increasing. Although the incidence rate appears to be generally 
rising over the last two decades, especially in the elderly, this is likely the result of 
improved diagnostic imaging8,11. At time of diagnosis, the median age of patients with 
GBM is 64 years old. The disease is about 60% more common in males than in females 
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and nearly twice as common in whites than in blacks2. Survival after diagnosis is highly 
variable and dependent on the tumor grade. GBM (WHO grade IV) is associated with the 
poorest prognosis amongst all gliomas. The overall survival at 5 years following 
diagnosis is merely 5.5%2. 
Approximately 5% of patients with malignant gliomas will report a family history 
of gliomas. Recent studies suggest a two-fold increased risk of developing brain tumors 
when a first-degree relatives is diagnosed with a glial tumor12,13. Genome-wide analysis 
has failed to identify a single genetic driver for familial cases of malignant gliomas that 
are not associated with rare genetic syndromes. In the absence of a single molecular 
driver contributing to the incidence rate of malignant gliomas, GBM is best explained 
with a polygenetic model where multiple mutations are involved and drive 
tumorigenesis14,15. 
Several observational studies have identified the relationship between radiation 
exposure and risk of malignancy. Ionizing radiation can induce DNA damage through 
molecular bond breakage and therefore, alter the molecular structure of DNA. In 
sufficient amounts, alteration in nucleic acid structure can overcome cellular DNA-repair 
mechanisms and lead to malignancy. Exposure to therapeutic doses or high-doses of 
radiation is the only clearly established risk factor for gliomas. Genetic factors can 
influence susceptibility from such risk factor8. Results of epidemiological studies 
assessing the risk of primary CNS brain tumor from diagnostic radiation imaging studies 
remain inconclusive to date. However, in the last two decades there has been a dramatic 
increase in the use of such diagnostic studies, which account for nearly half of per capita 
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radiation exposure. There is conclusive evidence that x- or gamma-irradiation exposure 
of at least 10-50 mSv is associated with a significant increased risk of malignancy16. This 
potential risk from radiologic diagnostic studies may be most relevant in the pediatric 
population because their brains are still growing and developing, however, data related to 
their risk following exposure is currently inconclusive. 
Epidemiological studies of other proposed risk factors such as head injury, foods 
containing N-nitroso compounds, occupational risk factors and electromagnetic field 
exposure is also inconclusive to date17. Although there have been growing concerns that 
increased radiofrequency exposure to the brain from cellular phones may lead to brain 
malignancy, the largest studies tracking incidence rates of glioma in Nordic countries, the 
United States, and Israel have found no significant changes in trend of glioma 
incidence11,18,19. Interestingly, many epidemiological studies have consistently reported 
an inverse relationship between glioma risk and atopic disease8,20,21. Although the 
mechanism by which this protective effect is achieved remains unclear, it has been 
hypothesized that increased surveillance by the innate immune system may account for 
the reduced glioma risk observed in this patient population. Further studies are required 
to clarify an important but unknown link between immune mediators and malignant 
gliomas. 
	9 
Classification 
 
Current WHO classification of primary CNS tumor relies heavily on morphological 
features to classify gliomas into categories based on the predominant cell type present, 
and are later assigned a grade according to the presence or absence of standard 
pathological features. Although this system provides valuable information regarding 
tumor prognosis, considerable heterogeneity exists within the same tumor grade. Recent 
advancement in molecular analysis have revealed that tumors with similar morphological 
features may have vastly different molecular signatures, bearing significant implications 
for disease prognosis and treatment responses22,23,24. 
In response to mounting evidence supporting the prognostic value of certain 
molecular alterations, the WHO published an updated version of its CNS tumors 
classification system that considers both histological features and molecular parameters 
to define specific tumor entities3. The incorporation of phenotypic-genotypic diagnostic 
criteria for CNS tumor classification adds another level of objectivity. It is hoped that this 
new classification system will help characterize tumors into more biologically 
homogenous entities to improve patient management and allow for improved prognostic 
determination and treatment response. Additionally, defining CNS tumors more narrowly 
and with greater diagnostic accuracy may facilitate clinical, experimental and 
epidemiological studies, which can lead to improvements in the quality of life of patients 
living with brain tumors. 
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The updated 2016 WHO classification of tumors of the CNS primarily relies on 
light microscopy to establish tumor grade. However, for diagnostic categories that have 
always been difficult to define, the addition of genotypic parameters helps establish the 
diagnosis and trumps the histological phenotype3. Although all astrocytic and 
oligodendroglial tumors were previously grouped into separate categories, this novel 
approach now clumps all diffusely infiltrating gliomas together regardless of their 
putative cell of origin3. This provides a dynamic classification system of tumors that 
share common growth patterns, behaviors, and genetic drivers in the isocitrate 
dehydrogenase 1/2 (IDH1 and IDH2) genes. Moreover, it groups tumors with similar 
prognostic parameters and may guide both conventional and targeted therapies for 
entities that share biological and genetic properties. As a result of this new classification, 
adult diffuse gliomas include WHO grade II and grade III astrocytic tumors, grade IV 
glioblastoma, as well as grade II and III oligodendrogliomas3.  
Glioblastoma may arise de novo or from lower grade astrocytic gliomas and is 
generally associated with dense cellular infiltrate into the brain parenchyma, 
pleomorphism, high mitotic activity and either microvascular proliferation, necrosis or 
both25. Additionally, the 2016 CNS WHO further divides glioblastoma into three distinct 
sub-types according to their molecular parameters. Glioblastoma, IDH-wildtype accounts 
for nearly 90% of cases and correlates clinically with primary glioblastoma3. These 
tumors arise de novo without clinical or histopathological evidence of a pre-existing 
lower grade glioma and typically present with a short clinical history (<3 months) in 
patients over 55 years of age3. The second sub-type, glioblastoma, IDH-mutant accounts 
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for approximately 10% of cases3. It corresponds most closely with secondary 
glioblastoma and preferentially arises in younger patients through malignant progression 
from a lower grade diffuse astrocytic glioma. The time required for this progression 
varies considerably but ranges from less than one year to more than ten years with a mean 
interval of 4-5 years3. The final sub-type, glioblastoma, NOS, is a diagnosis that is 
reserved for tumors for which IDH evaluation cannot be completed3. 
 
Diagnosis 
 
Patients affected by malignant glioma may present with a wide variety of signs and 
symptoms. The most common clinical presentation includes seizures, headaches, fatigue, 
focal neurological deficits, confusion, memory loss, and personality changes. Definitive 
diagnosis requires a biopsy with histologic confirmation to establish tumor type and 
grade26. Given the invasive nature of this procedure, imaging techniques such as 
magnetic resonance imaging or computed tomography are initially performed and can 
typically reveal findings that are strongly suggestive of an intracranial tumor. Malignant 
gliomas are defined by a heterogeneously enhancing mass with surrounding edema27. 
Furthermore, GBM is characterized by an area of central necrosis with peritumoral 
edema that is more prominent than that otherwise associated with lower grade gliomas27. 
Development of new imaging techniques such as diffusion-weighted imaging, diffusion 
tensor imaging, dynamic contrast-enhanced MRI, and perfusion imaging are increasingly 
used as diagnostic aids and provide additional information regarding vessel permeability 
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and cerebral blood flow volume. These new techniques may also be used as a mean to 
evaluate response to therapy28.  
 When the diagnosis is uncertain, proton magnetic resonance spectroscopy can 
help discriminate between a tumor, an area of necrosis, or a benign lesion. This technique 
detects level of various metabolites in the brain that correlate with areas of increased 
membrane turn-over and decreased neuronal cellularity, findings consistent with 
malignant gliomas27,28. Positive-emission tomography uses isotopes and is currently 
being investigated for its usefulness in diagnosing and monitoring responses to therapy in 
malignant gliomas29,30. 
 
Standard of care 
 
The standard of care for newly diagnosed GBM includes maximal surgical 
resection to the extent possible, followed by radiotherapy of the resection cavity in 
combination with temozolomide31,32. Surgical debulking of the tumor alone results in a 
median survival of 6 months. When combined with radiotherapy, the median survival rate 
improves to 12.1 months. The addition of TMZ, an oral alkylating agent that leads to 
DNA damage and induces apoptosis, has further extended the survival rate to 14.6 
months with minimal added toxicity6.  
The standard of care involves 6 weeks of focal, fractioned external beam 
radiotherapy to the surgical cavity including an additional 2 cm margin of surrounding 
brain tissue and concomitant TMZ6,33. Furthermore, primary brain tumors are commonly 
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associated with complex medical problems that require symptomatic management 
concurrent to standard of care. Seizures, cerebral edema, infections, depression, cognitive 
dysfunction, fatigue, and venous thromboembolisms are common complications that can 
significantly impact quality-of-life in brain cancer patients.  
The objective of surgery is to allow for maximal safe tumor resection without 
inadvertently damaging neurological functions34. Although this may not always be 
possible based on the surrounding anatomical structures involved, recent advancements 
in surgical imaging techniques have helped neurosurgeons distinguish neoplastic tissue 
from healthy surrounding neural tissue34–36. Fluorescence guided resection uses a dye that 
specifically binds to tumor cells and helps identify tumor margins when exposed to the 
appropriate wavelength. This technique results in increased gross total resection and 
improved progression-free survival 35–37. 
Biodegradable wafers impregnated with carmustine, another alkylating agent, are 
an alternative therapy for treatment of GBM38. The implant is placed within the tumor 
resection cavity and allows for the direct delivery of carmustine within the tumor bed for 
several weeks while limiting systemic toxicities. Unfortunately, the implant is associated 
with increased risk of infections, cerebral edema, and impaired wound healing, and 
therefore it is not commonly used by most centers38,39. 
Despite multimodality treatment, most patients will recur within 6.9 months, and 
prognosis is poor with a mean survival rate of only 3.3% at 2 years4,40. Surgery and 
radiotherapy are often contraindicated when the disease recurs. Enrollment into clinical 
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trials is often the best option for these patients, and novel agents and delivery methods are 
typically tested in the recurrent setting first.   
 
Gliomagenesis 
 
Recent work in genomics has made significant progress to further our understanding of 
gliomagenesis. It is now recognized that malignant progression results from sequential 
accumulation of genetic mutations and dysregulation of important growth signaling 
pathways and corresponding intracellular cascades. Abnormal proliferation is sustained 
through unregulated expression of growth factors such as vascular endothelial growth 
factors (VEGF), epidermal growth factors, and loss of tumor suppressor genes such as 
phosphotensin analogue (PTEN)4. Furthermore, a mutation in the epidermal-growth 
factor receptor (EGFR) known as EGFRvIII in primary GBM or increased expression of 
PDGF-A receptor (PDGFR) commonly associated with secondary GBM results in 
permanent activation of two key tyrosine kinase receptors (TKRs) and increased 
signaling through the RAS and PI3K transduction cascade4. These intracellular signaling 
cascades regulate gene expression involved in cellular growth and proliferation, 
cytoskeletal arrangement, apoptosis, mobility, and angiogenesis41. Activation of the 
above pathways results in increased expression of VEGF and angiogenesis. VEGF 
expression has been shown to correlate clinically with time to recurrence and overall 
survival34. Together, EGFR, PDGFR, and VEGF-receptor play a critical role in the 
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normal development of the nervous system by promoting proliferation of multipotent 
stem cells that may also contribute to gliomagenesis as explained below26,42. 
IDH1/IDH2 mutation is predominantly found in low-grade gliomas (>80%) and 
secondary high-grade gliomas24. Mutation in the IDH1/IDH2 genes is a process that 
occurs early in gliomagenesis and results in enzymatic alterations that leads to 
accumulation of 2-hydroxyglutarate, a possible oncometabolite24. These mutations are 
currently the subject of intensive research for the development of novel treatment 
strategies. 
Despite genetic differences, primary and secondary GBM are histologically 
indistinguishable and respond similarly to conventional therapy. By virtue of the specific 
biomarkers that define each subtype, they may respond differently to targeted molecular 
therapies or immunotherapies that are directed at specific molecular alteration. As such, 
identification and characterization of key genetic alterations in both primary and 
secondary GBM is an important step for the development of novel therapies that may 
improve clinical outcomes for patients. 
The nervous system contains neural stem cells that are located deep within the 
tumor bed. These BTSCs exhibit self-renewal capabilities, and are able to proliferate and 
differentiate into distinct cell lineages4,26,42. BTSCs or related progenitor cells may give 
rise to malignant gliomas by escaping from regulatory mechanisms that control 
proliferation and differentiation. There is mounting evidence that BTSCs are an important 
driver of disease recurrence and progression in GBM4,26,42. They secrete soluble factors 
that suppress immunity both within the tumor bed and systemically. Immunosuppression 
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within the tumor microenvironment is another hallmark of GBM that contributes to 
cancer survival. Moreover, they promote angiogenesis and tumor growth through 
unregulated expression of VEGF43. By virtue of their relative senescent state, BTSCs are 
resistant to conventional therapies. Radio-resistance is mediated through preferential 
activation of DNA-damage-expression pathways, whereas chemo-resistance occurs 
mostly through increased expression of O-6-methylguanine-DNA methyltransferase 
(MGMT), up-regulation of multiple-drug resistance genes and inhibition of apoptosis4,26. 
Interestingly, BTSCs are characterized by CD133, a biomarker also known as prominin 1 
that appears to be essential for the maintenance of BTSCs in GBM44,45. Together, these 
findings suggest that BTSCs may seed neoplastic cells that contribute to the primary 
malignancy. Eradication of GBM will likely require therapeutic strategies that effectively 
target this cell population. CD133 may provide a valuable target for future 
investigation46. 
Paul Ehrlich first introduced the notion that neoplastic cells originate 
spontaneously and that the immune system may recognize and eradicate them. Evidence 
of the immune system’s role in cancer surveillance can be witnessed by the increased 
incidence of virally induced cancers in immunosuppressed patients and by the direct 
correlation between tumor-infiltrating lymphocytes and patient survival47. The ability of 
the immune system to control and “shape” cancer is defined as immunoediting and can be 
characterized by three processes: elimination, equilibrium, and evasion. There is 
increasing evidence that the interplay between the immune system and neoplastic cells 
shapes and edits tumors by driving their expression profile so that they may escape 
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immune surveillance and proliferate unhampered. The evidence suggests that the 
interaction between GBM tumor cells, the stroma, and the immune factors are important 
factors in disease progression and clonal evolution. Giomagenesis is promoted by an 
immunosuppressive microenvironment that suppresses the function of T cells, antigen 
presenting cells (APCs), and NK cells, while also inhibiting T helper cells and cytotoxic 
T lymphocytes development47.  
Significant efforts to identify key biomarkers and understand gliomagenesis and 
tumor resistance mechanisms have lead to the development of treatment strategies 
designed to block essential signaling pathways, surpass acquired resistance, and improve 
the penetrance of the blood brain barrier to new therapeutics.  
 
Biomarkers  
 
In recent years, the development of sequencing technologies and large scale gene-
expression studies have helped recognize and confirm certain diagnostic, prognostic and 
predictive biomarkers which have advanced clinical trial designs and characterized GBM 
subgroups with more favorable prognosis and better response to therapy23. Furthermore, a 
greater understanding of the pathogenesis of GBM has opened the door to novel 
therapeutic avenues with expectation for better disease control and improved survival. 
Alone, tumor grading provides some insight into the clinical behaviors of CNS 
tumors, however, the combination of tumor grade with diagnostic molecular markers 
provides clinicians with further information regarding the predicted course of the disease 
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and treatment options available. Prognostic and predictive markers are additional tools 
used in oncology that can aid providers with clinical decisions by further redefining CNS 
tumors within each WHO subtype. Prognostic markers provide insight into the likely 
course of the disease without any intervention, whereas, predictive markers help predict 
the likely outcome of an intervention and can help clinicians decide between multiple 
therapies when available. Together, they are particularly helpful for targeted therapies 
which only function in tumors characterized by specific molecular markers23. However, 
the heterogeneity of gliomas in terms of histological features, grade, clinical outcomes, 
and genomic greatly complicates the risk stratification associated with certain 
biomarkers3. Despites these challenges, there is mounting evidence that MGMT 
methylation status, the IDH 1/2 mutation, and EGFRvIII are important biomarkers that 
can help guide clinical decisions along with other traditional prognostic indicators such as 
age, performance status, tumor location, and the extent of surgical resection 23,24,48. 
MGMT is an enzyme that repairs DNA damage in response to alkylating 
environmental pollutants, tobacco-specific carcinogens, and alkylating agents such as 
anti-cancer drugs. Since the amount of MGMT enzyme directly correlates with the ability 
of a cell to repair damaged DNA, MGMT expression levels provide key information 
regarding the susceptibility of a cell to alkylating agents. Therefore, MGMT expression is 
a marker of resistance in normal and neoplastic cells exposed to alkylating therapeutics49. 
Inversely, methylation of the MGMT promoter region results in epigenetic changes that 
lead to transcriptional inactivation of the MGMT gene and consequently lead to an 
increased susceptibility to alkylating agents. Methylation of the MGMT promoter region 
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is found in 35-45% of high-grade gliomas and approximately 80% of lower-grade 
gliomas50. MGMT methylation is a strong and independent prognostic marker associated 
with overall survival benefits and increased progression-free survival in high-grade 
gliomas51,52. In 2005, MGMT methylation status assessed by polymerase chain reaction 
in newly diagnosed glioblastoma was able to predict benefits from treatment with 
temozolomide, a potent alkylating therapeutic53. 
First identified in 2008, point mutations in the IDH1/IDH2 genes are now 
recognized as important diagnostic biomarkers. Although primary and secondary GBM 
are histologically indistinguishable, evidence strongly suggests that these tumors evolve 
through vastly different molecular pathways23. The mutation is easily detected through 
immunochemistry and is currently used to distinguish between primary glioblastoma, 
which does not harbor the mutated IDH genes, and secondary glioblastoma. Furthermore, 
non-glial cells never express the mutation, a feature that can be exploited to differentiate 
reactive gliosis from glioma54. Gliomas with the IDH1 and, less frequently, the IDH2 
mutation bear better prognosis than their wild-type counter part55. Thus, IDH1/IDH2 
status provides a better diagnostic and prognostic outlook for the clinician. 
EGFRvIII is a mutant of the EGFR that results in constitutive activation of the 
TKR and downstream signal transduction pathways. The mutation is associated with 
increased cellular proliferation and tumor invasiveness, radio and chemo-therapeutic 
resistance, and apoptosis inhibition56. It is expressed in approximately 30% of primary 
GBM and is rarely seen in secondary GBM. EGFRvIII expression is typically associated 
with overexpression of the wild-type EGFR which can be detected in about 50% of 
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GBM23,24,57. Long-term survival may be worse in patients whose tumors harbor this 
mutation, however, the prognostic value of EGFRvIII remains uncertain. Nonetheless, 
EGFRvIII provides an ideal target for targeted therapies as the mutant receptor is 
localized only on tumor tissue. EGFRvIII positive-cells are able to secrete micro-vesicles 
containing the EGFRvIII mRNA58. The detection of such vesicles in the serum of patients 
with EGFRvIII-positive GBM provides a potential biomarker to monitor treatment 
response and relapses58. 
CD133 and CD155 are biomarkers that are associated with GBM and may play an 
important role in future therapies. CD155 is an oncofetal cell adhesion molecule that is 
upregulated in specific cancers, including GBM59. It is expressed in BTSCs and has 
recently been the target of an oncolytic virus in a phase I trial59. CD133 is another marker 
of BTSCs that appears to be essential to GBM maintenance45. Further research is required 
to determine the value of these biomarkers.  
Despite these recent advancements in genomics, the extent of tumor resection, age 
at diagnosis and Karnofsky performance status remain the strongest prognostic factors 
associated with GBM60. Early age at diagnosis is significantly associated with survival 
benefit for all gliomas, but this relationship is most pronounced for GBM. 
 
Novel Therapies 
 
The discovery of distinct molecular expression profiles and specific genetic alterations 
has fostered interest in various molecular targeted agents. Preliminary data from phase 
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I/II clinical trials have supported the development EGFR antagonist, antiangiogenesis 
agents, and intracellular signaling pathway inhibitors61. Other approaches are currently 
investigating stem cell treatment and immunotherapies. 
Many of these aforementioned mutations affect TKRs and downstream signaling 
pathways. Molecular targeted therapies aim to block these receptors and inhibit 
downstream signaling cascades. Molecular targeted therapies can be divided into small 
molecule inhibitors and monoclonal antibodies. Small molecule inhibitors, many of 
which are tyrosine kinase inhibitors (TKIs), are lipophilic organic compounds able to 
cross cell membranes and function by selectively inhibiting intracellular tyrosine kinase 
domains or adaptor proteins involved in downstream signaling cascade5. Monoclonal 
antibodies are too large to cross the cell phospholipid bilayer and function by blocking 
extracellular proteins or disrupting ligand-receptor interaction at the cell surface5. In 
clinical trials, experimental treatments are typically tested once the disease recurs. 
However, they may also be conducted in combination with standard of care. Overall, 
these agents have demonstrated only modest therapeutic benefit with treatment responses 
between 0 to 15% and limited improvement in progression free survival62. 
Erlotinib and Gefitinib are both oral small molecule EGFR TKIs that selectively 
inhibit the receptor. Preclinical data showed that these agents exhibit prominent anti-
proliferative and anti-invasiveness effects along with potent EGFR inhibition and 
prolonged survival. Clinical trials have failed to demonstrate therapeutic benefits and 
have not improved clinical outcomes63. 
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Cetuximab is a monoclonal antibody that prevents EGFR activation by hindering 
ligand-receptor interaction. Cetuximab binding also results in internalization and 
downregulation of the EGFR4. Although preclinical models demonstrated decreased 
tumor growth and improved survival, clinical trials have shown only limited therapeutic 
benefit without significant improvement in patients’ outcomes5. 
Imatinib is another small molecule inhibitor that targets multiple kinases. It 
functions by inhibiting activation of the PDGFR and other RTKs. Clinical trials have 
failed to demonstrate therapeutic efficacy4,5. 
Angiogenesis is an important process that characterizes GBM and is mediated by 
VEGF secretion in the tumor microenvironment. Recent evidence suggests that VEGF 
expression correlates clinically with a shorter recurrence rate and is associated with a 
poorer prognosis. As a result, several molecular targeted therapies were developed to 
inhibit this growth pathway4,5. 
Bevacizumab is a monoclonal antibody that blocks ligand-receptor interaction by 
binding VEGF in the extracellular matrix. Clinical trials performed in the recurrent 
setting demonstrated improved clinical outcomes when bevacizumab was used in 
conjunction with radiotherapy and TMZ. In 2009, Bevacizumab was approved for used in 
GBM patients after disease recurrence64,65. However, bevacizumab failed to demonstrate 
overall survival benefits in new diagnosed GBM. It was associated with higher rates of 
toxicities that significantly decreased quality of life66.  
Several multikinase TKIs have also been investigated for their anti-angiogenic 
property in GBM. Cediranib and sunitinib exhibit predominant VEGF inhibition with 
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additional PDGFR and c-kit inhibition5. In spite of promising preclinical data, clinical 
trials have failed to demonstrate therapeutic benefit5. Vatalanib, another multikinase 
TKIs, with anti-VEGF and anti-PDGFR properties was also found to produce limited 
clinical benefits4,5. 
So far, small molecule TKIs have failed to demonstrate therapeutic benefit in 
patients with GBM. These findings are likely the result of multiple genetic alterations and 
signaling pathways that drive tumor growth in GBM. Intra-tumor heterogeneity and the 
lack of single dominant oncogenic mutation make small molecule TKIs that target a 
single growth pathway unlikely to be successful therapeutic options for GBM5. The 
ability to target multiple growth pathways at once through combination of multiple 
molecular targeted agents or designing small molecule inhibitors with specificity for 
multiple TKRs may offer greater efficacy. However, these approaches may also be 
associated with increased risk of toxicities from systemic inhibition31. To date, no 
combination therapy has proven to be superior to single agents4,5. 
Therapeutic strategies that combine both conventional therapies while harnessing 
the immune system to fight cancer are now available. Multiple options that aim to control 
and enhance the immune system are currently being investigated including checkpoint 
inhibitors, gene therapies, vaccine therapies, and oncolytic viruses46. 
Peptide vaccines are among the major immunotherapeutic strategies being 
investigated. They involve the direct administration of tumor associated antigens (TAAs) 
and trigger a specific immune response against antigens present solely on tumor cells to 
minimize the risk of autoimmunity. Rindopepimut, a well-known peptide vaccine, is 
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directed against EGFRvIII harboring tumor cells. Recently, a phase II clinical trial 
demonstrated that concurrent administration of Rindopepimut with temozolomide in the 
adjuvant phase of newly diagnosed GBM patients was safe and efficacious.  Overall, 
survival ranged from 21.8 to 26 months, and no symptomatic immune adverse effects 
were observed67. A phase III, international, randomized, double-blind, controlled study of 
rindopepimut/GM-CSF with adjuvant TMZ in newly diagnosed, surgically resected, 
EGFRvIII-positive GBM is currently underway. Results are expected to be available in 
early 201759. 
Dendritic cell (DCs) vaccines have been extensively studied for the treatment of 
GBM. DCs are professional APCs that play an important role in activating CD4+ and 
CD8+ lymphocytes. DCs vaccines require autologous activated DCs that are extracted 
through leukapheresis. Following extraction, the DCs are loaded with TAAs by pulsing 
apoptotic tumor cells, tumor lysate, or peptides. After reintroduction of activated DCs 
cells into the patient, they activate and stimulate a cytotoxic CD8+ and T helper CD4+ 
response to induce tumor cell death68, 69. Preliminary data from 20 patients treated with 
DCVax in combination with radiation therapy and TMZ showed a median overall 
survival rate of 36 months. Interestingly, two patients survived more than ten years after 
diagnosis70. 
A number of viruses exhibit selective tumor cell killing properties with the ability 
to trigger a range of inflammatory and immune stimulatory effects on the tumor itself, the 
brain tumor stromal components, and the peripheral immune system. The aim is to recruit 
an effector adaptive immune response against TAAs that can produce robust and long-
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lasting immunity. The PVS-RIPO virus is a nonpathogenic, recombinant Poliovirus: 
Rhinovirus chimera with tropism for tumor cell expressing CD155, an oncofetal cell 
adhesion molecule upregulated in ectodermal/neuroectodermal neoplasms including 
GBM59. The virus genome consists of the live attenuated poliovirus serotype 1 (Sabin) 
vaccine with its internal ribosomal entry site replaced with that of the human rhinovirus 
type 259. This IRES exchange completely ablates the inherent polio-virus pathogenicity in 
healthy neuronal tissue. No incidence of poliomyelitis were reported in safety studies71. 
The first in-human phase I clinical trial was started at Duke University in 2012 with 
histologically confirmed GBM patients whom were infused intratumorally with the PVS-
RIPO virus. So far, three patients have been disease-free for 23, 35 and 36 months after 
treatment72.  
 
Existing research 
 
Alkylating chemotherapeutic 
 
Prior to 2005, several clinical trials investigated the addition of various chemotherapeutic 
regimens to radiotherapy with limited clinical success. Following the results of a 
promising pilot phase II trial assessing the efficacy of concomitant and adjuvant 
administration of temozolomide with fractioned radiotherapy, a large randomized, 
multicenter, phase III trial was sponsored to compare radiotherapy plus TMZ versus 
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standard of care. All patients in the study had histologically confirmed newly diagnosed 
GBM6. 
 The study included 573 patients distributed over a total of 85 institutions. 
Candidates were randomly assigned to receive radiotherapy alone (n= 286) or 
radiotherapy plus temozolomide (n=287). Baseline characteristics were well-balanced, 
and cofounders such as age, prior debulking surgery, corticosteroid use, mini-mental 
status exam, and performance status were distributed similarly amongst both arms of the 
trial. Eighty-five percent of patients had their diagnosis reviewed and confirmed through 
the submission of histologic slides to an independent pathologist6.  
The primary goal of the study included overall survival, and the secondary goal 
was comprised of progression-free survival, safety, and quality of life. Statistics were 
analyzed with a Kaplan-Meier method, and the study was designed to have an 80% 
power at a statistical significance level of 0.05 to detect a 33% increase in median 
survival. Median follow up occurred at 28 months. At that time, 480 patients (84%) had 
died from their disease.  
Addition of TMZ to radiotherapy when compared to radiotherapy alone was 
statistically significant with an unadjusted hazard ratio of 0.63 (95% CI, 0.52-0.75; P< 
0.001). The overall median survival benefit from TMZ was 2.5 months. The median 
survival was 14.6 months (95% CI, 13.2-16.8) for radiotherapy plus TMZ and 12.1 
months (95% CI, 11.2-13.0) for radiotherapy alone. The two year survival rate was 
26.5% (95% CI, 21.2-31.7%) for radiotherapy plus TMZ and 10.4% (95% CI, 6.8-14.1%) 
for radiotherapy alone. Median progression-free survival was 6.9 months (95% CI, 5.8-
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8.2) for radiotherapy plus TMZ and 5.0 months (95% CI, 4.2-5.5) for radiotherapy alone. 
When adjusted for age, steroid use at the time of enrollment, gender, score on mini-
mental status exam, and tumor location, the hazard ratio for death in the radiotherapy-
plus-temozolomide group was 0.62 (95% CI, 0.51-0.75). Overall, the radiotherapy group 
did not show any high-grade hematologic toxic effects. On the other hand, 19 patients 
(7%) had grade 3 or 4 toxic effects in the radiotherapy-plus-temozolomide arm6. 
 In this study, Stupp et al. (2005) demonstrated that the addition of concomitant 
and adjuvant TMZ to radiotherapy early in the course of GBM provides statistically and 
clinically significant survival benefit. The addition of TMZ was associated with a median 
increase in survival of 2.5 months or a relative reduction in the risk of death of 37% with 
minimal added toxicities6. 
 
Prognostic and predictive value of MGMT promoter methylation 
 
Hegi et al. (2005) demonstrated the prognostic value of MGMT. Methylation of the 
promoter region was determined to be an independent prognostic factor regardless of 
treatment. MGMT promoter methylation (vs. unmethylated) was associated with a hazard 
ratio of 0.45 (95% CI, 0.32-0.61; P<0.001). Additionally, MGMT promoter methylation 
showed survival benefits from the addition of TMZ to radiotherapy with a median 
survival of 21.7 months (95% CI, 17.4-30.4) compared to 15.3 months (95% CI, 13-
20.9). Analysis by Kaplan-Meier estimate showed significant survival differences 
between the two groups (P= 0.007). Furthermore, absence of MGMT promoter 
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methylation showed statistically insignificant survival difference between the TMZ-
radiotherapy group and the radiotherapy-alone group. Thus, the results of this study 
suggest that therapy should be individualized to patients according to their MGMT 
promoter methylation status as they are most likely to benefit from the addition of 
TMZ53. 
In 2013, Gilbert et al. studied whether dose-dense (DD) TMZ offers survival 
benefits over conventional TMZ. DD TMZ depletes MGMT enzyme levels within 
mononuclear cells and possibly tumor cells, which may result in increased sensitivity to 
TMZ. Therefore, all 833 patients received radiotherapy and concomitant TMZ. At the 
conclusion of radiotherapy, they were randomly assigned to receive either adjuvant 
standard TMZ or DD-TMZ. Patients were stratified according to age, karnofsky 
performance status, extent of tumor resection, neurological function, and MGMT 
promoter methylation status51. 
The study revealed no statistically significant overall survival benefits from the 
addition of DD-TMZ compared to standard TMZ with a hazard ratio of 1.03 (95% CI, 
0.88-1.20; P=0.63). Median progression free survival was also not statistically significant 
with a hazard ratio of 0.87 (95% CI, 0.75-1.00; P=0.06). The study failed to demonstrate 
increased sensitivity to alkylating agents based on MGMT methylation status. However, 
the value of MGMT promoter methylation as a prognostic factor was further 
demonstrated from the result of this study. MGMT promoter methylation was associated 
with an improved overall survival rate compared to unmethylated promoter with a hazard 
ratio of 0.58 (95% CI, 0.58-0.69; P<0.001)51. 
	29 
Although most studies failed to reveal increased sensitivity to temozolomide in 
MGMT methylated tumors, a sub-group analysis has revealed the potential predictive 
value of MGMT in two sub-populations of high-grade gliomas. In 2012, two randomized 
clinical trials in elderly patients with glioblastoma demonstrated that methylated MGMT 
promoter is a strong predictive biomarker that is associated with benefit from treatment 
with temozolomide. The results of these randomized clinical trials strongly suggests that 
MGMT methylation status should be standardized and treatment options individualized 
for that age group51. The second sub-group investigated whether the IDH1 status 
influenced the prognostic versus predictive value of MGMT promoter methylation in 
anaplastic gliomas. The study concluded that MGMT promoter methylation is a 
predictive biomarker that confers benefits from alkylating agents in IDH1-wild-type but 
not IDH1-mutant malignant gliomas of WHO grade III-IV52. 
 
Prognostic value of EGFR 
 
A recent meta-analysis conducted by Thuy et al. (2015) attempted to determine the 
prognostic value of EGFR-positive GBM tumors. The median survival difference for 
patients characterized by EGFR-positive tumor was 0.15 month (95% CI, -0.20-0.49; 
P=0.394) when compared to EGFR-negative tumors. Additionally, the median survival 
difference for GBM patients characterized by the EGFRvIII variant was -0.6 month (95% 
CI, -2.18-0.98; P=0.457). Together, the results of this study suggest that EGFR bears no 
significance with respect to disease prognosis.  
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 The study had several limitations. First, the study included observational studies 
(prospective and retrospective), case series, and data from clinical trials and each study 
design was treated equally during the analysis. Case series do not provide the same power 
as clinical trials and should not be considered to provide the same level of evidence. 
Furthermore, methods of data collection differed significantly between studies and 
ranged from immunohistochemistry, in situ hybridization, and polymerase chain reaction. 
These methodologies do not have the same sensitivity and this variability introduces a 
degree of uncertainty that could be accounted for. Finally, the authors designed the study 
to categorize biomarkers into categories based on what they deemed clinically significant. 
Thus, a survival benefit >3 months was arbitrarily defined as a meaningful change. 
Nonetheless, the methodology offered by Thuy et al. (2015) was able to replicate results 
from several studies, confirming the prognostic value of MGMT and IDH1. More studies 
are required to determine the prognostic value of EGFR in GBM73. 
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METHODS 
Study design 
A curriculum for continuing medical education (CME) will be developed in a lecture-
based format to inform PCPs of the different prognostic value and treatment options 
associated with specific biomarkers. 
 
Study population and sampling 
The hour-long lecture will be offered at medical conferences in partnership with national 
primary care organizations. This curriculum will allow PCPs to gain CME credits in 
return for their participation. The lecture will also be available to health care providers 
and researchers with a special interest in the field. The objective of the lecture is to 
increase health care providers’ knowledge of newly discovered biomarkers in GBM 
patients that bear prognostic value. 
 The purpose of this curriculum is to provide a meaningful increase in knowledge 
acquisition. The parameters of the study entail an 80% passing grade and an expected 
improvement score of 15% in the post-test following the lecture with a statistical 
significance level of 0.05 and 80 percent power. In order to meet the sample size criteria, 
the curriculum should be offered to a minimum of 28 persons74. Offering the curriculum 
at a minimum of three conferences, one for each association, will meet the minimum 
requirement for statistical significance. 
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Recruitment 
Participants of the study will be solicited amongst providers attending CME national 
conventions where the curriculum will be presented. Enrollment into the study will be 
voluntary and will occur after informed consent is provided. Advertisement of the lecture 
will include website publications by each participating organization, email and letter 
delivery to subscribed members of each association, and mass distribution to universities, 
hospitals, and research institutions. Offering the curriculum at a wide range of 
conferences and locations will maximize our ability to reach providers throughout the 
country and spread awareness of novel biomarkers with prognostic value as well as novel 
therapeutic approaches currently being investigated.  
 In return for their participation, attendees will receive one hour of CME credit. 
The disproportionally high level of comorbidities and deaths associated with GBM will 
also provide an incentive for PCPs to attend the lecture. Being educated on the state of 
the art development in the field of neuro-oncology will allow PCPs to share this 
knowledge with their patients and better guide clinical decision. 
 
Curriculum 
The presentation will be developed using Microsoft PowerPoint. It will begin with a 
concise outline of the learning objectives, which are listed below in Table 1. The learning 
objectives will provide guidelines to the attendees and help focus their attention to core 
aspects we hope they retain from the presentation. Additional key issues for discussion 
will include: 
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• Brief review of the epidemiology and pathogenesis of GBM 
• Current therapeutic modalities 
• Prognostic and predictive value of biomarkers 
• Involvement of BTSCs in disease recurrence and treatment failure 
• Outlook on future therapies 
Table 1. Learning Objectives of the Curriculum 
By completing the curriculum, the learner will be qualified to: 
1. Recognize the key molecular alterations and growth pathways involved in the 
malignant progression of GBM 
2. List the different treatment modalities available for patients with GBM  
3. Evaluate the risks versus benefits of diagnostic imaging, especially in the 
pediatric population 
4. Recognize the therapeutic value of important biomarkers associated with GBM 
5. Understand the role of BTSCs in disease recurrence and resistance to 
conventional therapy 
6. Understand the emerging role of immunotherapies and latest research 
development in the field  
 
Curriculum Assessment 
A pre- and post-test will be the main method of assessment. All attendees of the lecture 
will be asked to complete these tests. The tests will be administered using the attendees’ 
mobile phones and results will be collected through Poll Everywhere, a mobile device 
survey application. Data from the pre-test will help assess the baseline understanding of 
current therapeutic strategies used to eradicate GBM. The post-test will consist of the 
same questions used before and will be administered at the end of the lecture. Data from 
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the post-test will allow for a comparison of their acquired knowledge from the 
presentation and its effectiveness. 
 
Study variables and measures 
The study variables will consist of a pre- and post-test, each consisting a minimum of ten 
multiple-choice questions. The questions will cover topics included in the learning 
objectives as well as the following points: 
1. Key demographic affected by GBM 
2. Important growth factors involved in malignant gliomas 
3. Surgical techniques 
4. Logistics of fractioned external beam radiotherapy and TMZ combination therapy 
5. Antiangiogenic therapy in the recurrent setting 
6. Symptomatic management of commonly associated medical issues 
7. Risk associated with ionizing radiation 
8. MGMT methylation status and IDH1/IDH2 biomarker 
9. Importance of the tumor microenvironment and BTSCs in disease recurrence and 
treatment failure 
10. Outlooks on immunotherapies currently under investigation 
Furthermore, the survey will collect basic demographic information to gain a greater 
understanding of the participant involved in the study. The information collected will 
include: age, gender, medical specialty, work setting, and geographic location. 
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Data collection 
The pre-test will be performed prior to the start of the lecture. Data will be collected with 
the use of a mobile device survey application that allows answers to be pooled and 
analyzed. Immediately following the lecture, the post-test will be administered and 
results will be pooled with the pre-test data. Finally, the post-test will be graded with a 
passing score of 80%, and correct answers will be displayed on the screen. This method 
will allow attendees to determine whether knowledge gained from the lecture helped 
them performed better during the post-test. Additionally, all pre- and post-test data 
collected during the year will be pooled together for further analysis. Other survey 
methods such as pen and paper, or emailed surveys are unlikely to yield the same 
participation rate. 
 
Data analysis 
Following data collection, a paired t-test will be conducted comparing pre-test and post-
test results. The mean of both tests will be analyzed and compared to determine if the 
presentation represents an effective curriculum for delivering the latest information 
regarding the prognostic value and treatment options associated with specific biomarkers. 
Furthermore, an item analysis will be conducted to determine which aspects of the 
presentation work well and which are in need of improvement. The results of these 
analyses will assist us in determining whether the learning objectives have been achieved. 
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Timeline and resources 
The presentation will be submitted to CME accredited conferences to gain approval and 
ensure that high educational standards are maintained throughout. Accreditation from 
national organizations such as the AAPA will be required to perform the lecture at 
national medical conventions. Accreditation from these organizations will ensure that a 
standard level of criteria is met. 
Several medical conferences are held throughout the year at various locations in 
the United States. After completion of the accreditation process, specific conferences will 
be selected with the aim of offering CME to a wide variety of PCPs including family 
physicians, physician assistants, and nurse practitioners. Targeting a large number of 
providers involved in primary care, whom are often first to suspect a diagnosis of brain 
tumor, will increase the extent of our reach among vast patient populations and ensure 
that proper treatment is provided.  
 
Institutional Review Board  
The proposed methodology will be presented for IRB approval to the Boston Medical 
Center IRB under 45 CFR 46.101 (b) criteria for educational purposes. 	
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CONCLUSION 
Discussion 
This work provides a review of the most recent literature pertaining to clinically 
significant prognostic biomarkers and therapeutic options available to patients with 
GBM. Despite considerable research, this review highlights the need for the development 
of new therapeutic strategies in order to tackle the insidious nature of GBM. This 
curriculum will allow health care providers to gain a greater understanding of the 
molecular drivers of GBM. Furthermore, it will provide an important perspective into the 
most recent development and challenges associated with treatment of GBM. 
 This curriculum will be offered at select national conferences to educate all PCPs 
such as physicians, physician assistants, and nurse practitioners whom are interested in 
learning about conventional and experimental therapeutic strategies. 
 Limitations to the curriculum include a low attendance rate at CME conferences. 
This study may not reach statistical significance if less than 28 participants attend the 
lecture. Given that many of the approaches presented above are still experimental, limited 
information from large randomized double-blind placebo-controlled trials is available. As 
such, additional research will be required before these approaches can be translated into 
clinical practice.  
CME accreditation will compensate PCPs for their attendance while serving as an 
additional incentive for their participation. Targeting multiple providers at various 
conferences hosted by nationally recognized organizations allows us to extend our reach 
	38 
to more patients and ultimately help them make better informed decisions regarding their 
course of treatment. 
 
Summary 
GBM is the most invasive and commonly occurring glioma subtype in adults. The disease 
is associated with a poor prognosis, and at the time of its diagnosis, it is often rapidly 
progressing. To date, first line therapy includes maximal safe surgical resection, 
radiotherapy, and concomitant and adjuvant chemotherapy in newly diagnosed GBM 
patients. Unfortunately, disease recurrence is common. A variety of therapies have been 
tested in the recurrent setting with the hope of improved clinical outcomes.  
Recently, several biomarkers that correlate with better prognosis have been 
identified. These markers have also been the focus of intensive research efforts for the 
development of novel therapies. The following summary provides a brief introduction 
into the most clinically relevant biomarkers, a rationale for treatment failure observed 
with current therapies, and a perspective on future therapies. 
Genome-wide analysis studies have identified IDH1/IDH2, MGMT methylation 
status, and EGFRvIII as important biomarkers that bear prognostic and predictive value. 
Mutation in the IDH1 and IDH2 genes provides both diagnostic and prognostic 
information to health care providers. The mutation is diagnostic for secondary GBM, 
which is associated with a slightly better prognosis, primarily because it reflects greater 
sensitivity to radio- and chemotherapy. MGMT expression is associated with resistance 
to alkylating agents. There is growing evidence to support that chemotherapy with TMZ 
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should be individualized according to a patient’s MGMT methylation status. EGFRvIII is 
a mutation almost exclusively located on primary GBM. While the mutation may be 
associated with a poor prognosis, the value of this biomarker remains controversial. The 
receptor is the target of multiple small molecule inhibitors and monoclonal antibodies. 
Thus far, no therapies targeting the EGFR and downstream intracellular signaling cascade 
have resulted in meaningful clinical improvements in the standard of care.  
 Multiple lines of evidences have highlighted the role of BTSCs in disease 
recurrence and resistance to conventional therapies. It has been hypothesized that BTSCs 
exist within the tumor bed and contribute to primary tumors as well as disease recurrence. 
These cells exhibit self-renewal capabilities and inherent resistance to radio- and 
chemotherapy by virtue of their relative senescent state. Additionally, BTSCs contribute 
to the immunosuppressive microenvironment that is characteristic of GBM by expressing 
cell surface molecules and secreting soluble factors that suppress the immune system. 
Together, these important processes drive clonal evolution, a mechanism by which tumor 
cells become resistant to therapy and evade immune detection.  
In recent years, it has become apparent that molecular targeted therapies with 
specificity for a single receptor or growth pathway will not be effective in eradicating a 
highly heterogeneous tumor characterized by multiple genetic alterations. Therapeutic 
strategies that target BTSCs will likely be required to completely eradicate GBM. 
Approaches that combine the use of standard therapies with immunotherapies are 
currently being investigated. Theoretically, cell-based vaccines or oncolytic viruses have 
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the ability to stimulate a robust and long-lasting immune response that can specifically 
target BTSCs and tumor cells that express specific immunogenic markers. 
  No widespread platform currently exists for providers to learn about the latest 
development in neuro-oncology because many of these therapies are still being 
investigated. This curriculum serves to educate primary health care providers on state of 
the art development in research and latest literature in the field. In the near future, 
immunotherapies alone or in combination with conventional therapies may become 
available to patients. It is crucial that providers learn about these therapies so they may 
appropriately advise their patients.  
 
Clinical and/or public health significance 
Despite its relatively rare incidence, GBM is associated with a disproportionally high 
level of comorbidities and deaths. In recent years, several therapeutic approaches have 
failed to demonstrate significant clinical benefit. Recognition of important prognostic 
biomarkers and potential new therapies is an important step to appropriately counsel 
patients on potential treatment options. 
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LIST OF JOURNAL ABBREVIATIONS 
 
AAFP American Academy of Family Physicians 
Acta Neuropathol (Berl) Acta Neuropathologica (Berl) 
Am J Neuroradiol (AJNR) American Journal of Neuroradiology 
Annu Rev Pathol Annual Review of Pathology: Mechanisms of Disease 
Arch Neurol Archives of Neurology 
Asian Pac J Cancer Prev 
(APJCP) 
Asian Pacific Journal of Cancer Prevention  
Biochim Biophys Acta 
(BBA) 
Biochimica et Biophysisca Acta 
The BMJ BMJ: British Medical Journal 
Brain Pathol Zurich Switz Brain Pathology (Zurich, Switzerland) 
CA Cancer J Clin CA: A Cancer Journal for Clinicians 
Cancer Chemother 
Pharmacol 
Cancer Chemotherapy and Pharmacology 
Cancer Epidemiol Biomark 
Prev Publ Am Assoc Cancer 
Res Cosponsored Am Soc 
Prev Oncol 
Cancer Epidemiology, Biomarkers & Prevention 
Published by the American Association for Cancer 
Research Cosponsored by the American Society of 
Preventive Oncology 
Cancer Genet Cancer Genetics 
Cancer Res Cancer Research 
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Chin J Cancer  Chinese Journal of Cancer 
Clin Med Insights Oncol Clinical Medicine Insights: Oncology 
Cochrane Database Syst 
Rev 
Cochrane Database System of Reviews 
Curr Pharm Des Current Pharmaceutical Design 
Epidemiol Camb Mass Epidemiology (Cambridge, Mass.) 
Eur J Neurol European Journal of Neurology 
Expert Rev Anticancer Ther Expert Review of Anticancer Therapy 
Front Immunol Frontiers in Immunology 
Genet Epidemiol Genetic Epidemiology 
Handb Clin Neurol Handbook of Clinical Neurology 
Hematol Oncol Clin North 
Am 
Hematology/Oncology Clinics of North America 
Int J Biochem Cell Biol The International Journal of Biochemistry & Cell Biology 
J Clin Oncol Off J Am Soc 
Clin Oncol 
Journal Clinical Oncology Official Journal of American 
Society of Clinical Oncology 
J Clin Neurosci Journal of Clinical Neuroscience 
J Mol Diagn (JMD) Journal of Molecular Diagnostics  
J Mol Med Berl Ger Journal of Molecular Medicine (Berlin, Germany) 
J Natl Cancer Inst Journal of the National Cancer Institute 
J Nucl Med Off Publ Soc 
Nucl Med 
The Journal of Nuclear Medicine Official Publication of 
the Society Nuclear Medicine 
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JAMA The Journal of the American Medical Association 
Lancet Oncol The Lancet Oncology 
N Engl J Med New England Journal of Medicine 
Nat Med Nature Medicine 
Neuro-Oncol Neuro-Oncology 
Neuroimaging Clin N Am Neuroimaging Clinics of North America 
Neurol Clin Neurologic Clinics 
Neurosurg Clin N Am Neurosurgery Clinics of North America 
Neurol Res Int Neurology Research International  
Neurosurg Rev Neurosurgical Review 
Oncol Williston Park N Oncology (Williston Park, NY) 
Pharmacol Ther Pharmacology & Therapeutics 
Stem Cells Dayt Ohio Stem Cells (Dayton, Ohio) 
Surg Neurol Int Surgical Neurology International 
Trends Mol Med Trends in Molecular Medicine 
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